| 1. |
|
|
| 2. |
- Göthe-Lundgren, Maud, et al.
(author)
-
Cost allocation in collaborative forest transportation
- 2010
-
In: European Journal of Operational Research. - : Elsevier BV. - 0377-2217 .- 1872-6860. ; 205:2, s. 448-458
-
Journal article (peer-reviewed)abstract
- Transportation planning is an important part of the supply chain or wood flow chain in forestry. There are often several forest companies operating in the same region and collaboration between two or more companies is rare. However, there is an increasing interest in collaborative planning as the potential savings are large, often in the range 5–15%. There are several issues to agree on before such collaborative planning can be used in practice. A key question is how the total cost or savings should be distributed among the participants. In this paper, we study a large application in southern Sweden with eight forest companies involved in a collaboration. We investigate a number of sharing mechanisms based on economic models including Shapley value, the nucleolus, separable and non-separable costs, shadow prices and volume weights. We also propose a new allocation method, with the aim that the participants relative profits are as equal as possible. We use two planning models, the first is based on direct flows between supply and demand points and the second includes backhauling. We also study how several time periods and geographical distribution of the supply and demand nodes affect the solutions. Better planning within each company can save about 5% and collaboration can increase this about another 9% to a total of 14%. The proposed allocation method is shown to be a practical approach to share the overall cost/savings.
|
|
| 3. |
- Göthe-Lundgren, Maud, 1952-, et al.
(author)
-
Cost allocation in forestry operations
- 2006
-
In: 12th IFAC Symposium on Information Control Problems in Manufacturing,2006. - Paris : Elsevier Science.
-
Conference paper (peer-reviewed)abstract
|
|
| 4. |
|
|
| 5. |
- Alm Mårtensson, Anna, et al.
(author)
-
Att möta våldsutsatta äldre personer
- 2022
-
In: Äldre personers utsatthet för våld i nära relationer. - Lund : Studentlitteratur AB. - 9789144155142 ; , s. 183-220
-
Book chapter (other academic/artistic)
|
|
| 6. |
- Alm Mårtensson, Anna, et al.
(author)
-
Att möta våldsutsatta äldre personer
- 2022
-
In: Äldre personers utsatthet för våld i nära relationer. - : Studentlitteratur AB. - 9789144155142 ; , s. 183-220
-
Book chapter (other academic/artistic)abstract
- Frågor om våld i nära relationer är numera vanligt förekommande i media, politiska debatter, offentliga utredningar och lagändringar. Men trots detta uppmärksammas sällan äldre personers utsatthet för våld. Anledningarna kan vara flera, men tanken på att äldre kan utsättas för våld i en nära relation är för många avlägsen.Äldre personers utsatthet för våld i nära relationer vill synliggöra att olika typer av våld förekommer mot och bland äldre personer. Men det allra viktigaste är att ge kunskap om hur omgivningen kan uppmärksamma detta och förhindra våld, samt ge hjälp och stöd. Boken belyser det ansvar som olika myndigheter, såsom socialtjänst, hälso- och sjukvård samt tandvård, har. Ett kapitel beskriver rättsprocessen vid en anmälan och ett annat belyser vilka svårigheter en äldre person kan ha när det gäller att söka hjälp och att bryta upp från en relation. Flera kapitel innehåller konkreta råd för hur exempelvis personal kan ge hjälp och stöd.Äldre personers utsatthet för våld i nära relationer är i första hand skriven för högskoleutbildningar inom socialt arbete, vård, omsorg och medicin. Boken kan också vara till nytta för alla som vill öka sin kunskap om äldre personers utsatthet för våld i nära relationer.
|
|
| 7. |
- Anand, Vibha, et al.
(author)
-
Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes : Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S
- 2021
-
In: Diabetes Care. - : American Diabetes Association. - 1935-5548 .- 0149-5992. ; 44, s. 2269-2276
-
Journal article (peer-reviewed)abstract
- OBJECTIVE: To combine prospective cohort studies, by including HLA harmonization, and estimate risk of islet autoimmunity and progression to clinical diabetes.RESEARCH DESIGN AND METHODS: For prospective cohorts in Finland, Germany, Sweden, and the U.S., 24,662 children at increased genetic risk for development of islet autoantibodies and type 1 diabetes have been followed. Following harmonization, the outcomes were analyzed in 16,709 infants-toddlers enrolled by age 2.5 years.RESULTS: In the infant-toddler cohort, 1,413 (8.5%) developed at least one autoantibody confirmed at two or more consecutive visits (seroconversion), 865 (5%) developed multiple autoantibodies, and 655 (4%) progressed to diabetes. The 15-year cumulative incidence of diabetes varied in children with one, two, or three autoantibodies at seroconversion: 45% (95% CI 40-52), 85% (78-90), and 92% (85-97), respectively. Among those with a single autoantibody, status 2 years after seroconversion predicted diabetes risk: 12% (10-25) if reverting to autoantibody negative, 30% (20-40) if retaining a single autoantibody, and 82% (80-95) if developing multiple autoantibodies. HLA-DR-DQ affected the risk of confirmed seroconversion and progression to diabetes in children with stable single-autoantibody status. Their 15-year diabetes incidence for higher- versus lower-risk genotypes was 40% (28-50) vs. 12% (5-38). The rate of progression to diabetes was inversely related to age at development of multiple autoantibodies, ranging from 20% per year to 6% per year in children developing multipositivity in ≤2 years or >7.4 years, respectively.CONCLUSIONS: The number of islet autoantibodies at seroconversion reliably predicts 15-year type 1 diabetes risk. In children retaining a single autoantibody, HLA-DR-DQ genotypes can further refine risk of progression.
|
|
| 8. |
- Bask, Mikael, et al.
(author)
-
Market power in the expanding Nordic power market
- 2011
-
In: Applied Economics. - : Taylor & Francis. - 0003-6846 .- 1466-4283. ; 43:9, s. 1035-1043
-
Journal article (peer-reviewed)abstract
- We examine if the Nordic power market, Nord Pool, has been competitive or if electricity suppliers have had market power. Specifically, since the evolution from national markets to a multi-national and largely deregulated power market has taken place stepwise, we also examine how the degree of market power has evolved during this integration process. The Bresnahan-Lau method together with weekly data during 1996-2004 are used in the analysis, which shows that electricity suppliers have had small, but statistically significant, market power, but that the market power has been reduced as the Nord Pool area has expanded
|
|
| 9. |
|
|
| 10. |
- Battaglia, Manuela, et al.
(author)
-
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
- 2020
-
In: Diabetes Care. - : American Diabetes Association. - 1935-5548 .- 0149-5992. ; 43:1, s. 5-12
-
Journal article (peer-reviewed)abstract
- The clinical diagnosis of new-onset type 1 diabetes has, for many years, been considered relatively straightforward. Recently, however, there is increasing awareness that within this single clinical phenotype exists considerable heterogeneity: disease onset spans the complete age range; genetic susceptibility is complex; rates of progression differ markedly, as does insulin secretory capacity; and complication rates, glycemic control, and therapeutic intervention efficacy vary widely. Mechanistic and immunopathological studies typically show considerable patchiness across subjects, undermining conclusions regarding disease pathways. Without better understanding, type 1 diabetes heterogeneity represents a major barrier both to deciphering pathogenesis and to the translational effort of designing, conducting, and interpreting clinical trials of disease-modifying agents. This realization comes during a period of unprecedented change in clinical medicine, with increasing emphasis on greater individualization and precision. For complex disorders such as type 1 diabetes, the option of maintaining the "single disease" approach appears untenable, as does the notion of individualizing each single patient's care, obliging us to conceptualize type 1 diabetes less in terms of phenotypes (observable characteristics) and more in terms of disease endotypes (underlying biological mechanisms). Here, we provide our view on an approach to dissect heterogeneity in type 1 diabetes. Using lessons from other diseases and the data gathered to date, we aim to delineate a roadmap through which the field can incorporate the endotype concept into laboratory and clinical practice. We predict that such an effort will accelerate the implementation of precision medicine and has the potential for impact on our approach to translational research, trial design, and clinical management.
|
|
